The Efficacy of Endoscopic Palliation of Obstructive Jaundice in Hepatocellular Carcinoma

Semi Park,1,2 Jeong Youp Park,3 Moon Jae Chung,3 Jae Bock Chung,3 Seung Woo Park,3 Kwang-Hyub Han,3 Si Young Song,3,4 and Seungmin Bang3

1Department of Internal Medicine, Graduate School, Yonsei University College of Medicine, Seoul; 2Center for Health Promotion, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul; 3Division of Gastroenterology, Department of Internal Medicine, Yonsei Institute of Gastroenterology, Yonsei University College of Medicine, Seoul; 4Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.

Received: July 12, 2013
Revised: December 12, 2013
Accepted: December 13, 2013
Corresponding author: Dr. Seungmin Bang, Division of Gastroenterology, Department of Internal Medicine, Yonsei Institute of Gastroenterology, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea. Tel: 82-2-2228-1995, Fax: 82-2-393-6884 E-mail: bang7028@yuhs.ac

© Copyright: Yonsei University College of Medicine 2014
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Jaundice is a common presentation of hepatocellular carcinoma (HCC) and occurs in 5–44% of patients. However, obstructive jaundice is quite uncommon in HCC...
with an incidence of 0.5–13%.1 The synonyms for obstructive jaundice in HCC are icteric type hepatoma or cholestastic type HCC.2 Obstructive jaundice in HCC can be caused by tumor thrombus in the bile duct, hemobilia, and extrinsic tumor compression of the extrahepatic biliary tree.

In Korea, the death rate of HCC has been reported at 21.8/100,000 in 2011 by the National Cancer Information Center; HCC has the second highest cancer mortality next to lung cancer. The prognosis for patients with hepatocellular jaundice in HCC is dismal. On the other hand, the prognosis for patients with obstructive jaundice caused by extra-hepatic duct obstruction is better.23 The mean survival of patients with obstructive jaundice caused by HCC treated with simple biliary drainages varies from 2.5 to 4.5 months, and when treated with combined palliative therapies, it ranges from 8 to 13.4 months.1 Therefore, in cases of obstructive jaundice complicated by HCC, active endoscopic intervention, including endoscopic retrograde cholangiopancreatography (ERCP), could improve the prognosis.

However, the role of endoscopic intervention in HCC is not yet clearly defined. It is important to predict the outcomes of invasive interventions in patients with HCC, who have a bleeding tendency and other various conditions that can increase the rate of treatment-related complications. The aim of this study was to analyze the clinical characteristics of patients with obstructive jaundice caused by HCC who underwent endoscopic intervention and to identify predictors of successful outcomes.

**MATERIALS AND METHODS**

We included 54 patients with HCC who were treated from 1999 to 2009 with ERCP for obstructive jaundice at Severance Hospital, Yonsei University College of Medicine, in Seoul, Korea. The median age of the patients was 56.3 years (range: 38 to 78 years). Forty-seven patients (87%) were male. The diagnosis of HCC was based on either typical imaging findings on abdominal CT, liver MRI, or hepatic angiography, combined with elevated tumor markers such as α-fetoprotein (AFP); vitamin K absence or antagonist II (PIVKA-II); or pathologic confirmation.

Obstructive jaundice was diagnosed by the typical sign of biliary tree obstruction (narrowing and dilatation at distal and proximal parts of the biliary tract) on imaging studies and biochemical abnormalities, such as elevated total and direct bilirubin. Mechanisms of obstructive jaundice in HCC were divided into three groups: type 1 obstruction due to an intraluminal obstruction of the bile duct caused by a tumor thrombus or floating tumor fragments; type 2 caused by hemobilia; and type 3 due to extraluminal tumor or nodal compression.14 Locations of biliary obstruction were classified according to the extent of tumor thrombi or obstruction. Location of obstruction was mainly diagnosed by ERCP. The locations of obstruction were divided into six groups: the type I location of obstruction was an obstruction of a unilateral intrahepatic duct (IHD) with a biliary tumor thrombi or tumor compression, without contralateral IHD involvement. The type II location of obstruction involved a unilateral IHD with hilar area involvement. Type III obstruction was defined by obstruction of a bilateral IHD with hilar involvement. Type IV obstruction involved only extrahepatic ducts (EHD). Type V location of biliary obstruction comprised multifocal involvement of both the IHD and EHD, and Type VI obstruction was defined as solitary hilar or common hepatic duct (CHD) involvement.

Endoscopic intervention was performed by insertion of a biliary plastic stent or metal stent, endoscopic nasobiliary drainage (ENBD), or sphincterotomy (EST) alone. The method of intervention was decided upon by the endoscopists at the time of intervention. We primarily tried to insert a biliary stent for treatment of HCC patients with obstructive jaundice. However, stent insertion was not available in some cases with severe bile duct stenosis, etc. In such cases, other endoscopic interventions, such as ENBD or EST, were selected.

Biliary stent insertion was performed with plastic or metal stents. Plastic stents showed relatively shorter patency than that of metal stents. Therefore, inoperable cancer patients with obstructive jaundice preferred to have metal stents inserted than plastic stents. In this study, although this result did not show statistical significance, metal stents were inserted in cases with intraluminal tumor infiltration. On the other hand, plastic stents tended to be used in patients with obstructive jaundice caused by hemobilia or extraluminal compression.

The patients were divided into two groups based on the success or failure to relieve obstructive jaundice. Clinical success was defined as a bilirubin level that decreased to normal bilirubin status or more than half the bilirubin level compared to that in the time of ERCP within 4 weeks after endoscopic intervention.

**Statistical analysis**

Continuous data were expressed as mean±SD or medians,
and categorical data were expressed as the number of patients with a specified condition or clinical variable. The detection of significant differences was performed using Student’s t-test for continuous variables and the chi-square test for categorical variables. Logistic regression was carried out via multivariate analysis. These tests were also used to determine whether each variable considered was a significant predictor of clinical outcomes (success or failure). For predicting clinical outcomes, a cut-off value for pre-endoscopic treatment total bilirubin level was determined using receiver operating characteristic (ROC) curves and area under the ROC curve analysis. Median overall survival was estimated using Kaplan-Meier analysis. All analyses were performed using SPSS software (ver. 12.0, Chicago, IL, USA). All p-values <0.05 were considered significant.

RESULTS

The clinical characteristics of the patients are summarized in Table 1. Viral hepatitis B or C was the predominant underlying cause of liver disease (n=48, 88.9%), and most of the patients had cirrhosis (n=47, 87%). Hepatic function was evaluated with Child-Pugh classification and the numbers of patients with Child-Pugh class A, B, and C were 7 (13%), 21 (39%), and 26 (48%), respectively. At the time of ERCP, the mean total bilirubin was 15.5 mg/dL, mean serum alkaline phosphatase was 280.2 IU/L, and mean gamma-glutamyl transferase was 272.4 IU/L (Table 1).

The mechanisms of obstructive jaundice, locations of biliary obstruction, and modalities of endoscopic interventions are summarized in Table 2 and 3. The mechanisms of obstructive jaundices in HCC were as follows: intraluminal tumor thrombosis (n=17), cancer infiltration (n=35), hemobilia (n=6), compression by tumor mass (n=7) or lymph node (n=3), or a combination of the above. Among them, type 1 obstructive jaundice (intraluminal tumor obstruction) was most common. Each type of obstructive jaundice may have been combined with other types in some cases. For the location of obstructions, the most common level of biliary obstruction involved hilar lesions or common hepatic ducts (type VI). Endoscopic interventions included ENBD (n=6), plastic stent (n=17), metal stent (n=16), and EST (n=12). Stent insertion was preferentially considered in endoscopic intervention. However, stent could not be inserted in some cases. We tried to perform ENBD for cases that showed bile duct stricture caused by cancer, huge abscess, or ampullary adenoma.

Even less, ENBD insertion could not be possible in specific cases with bile duct stenosis by post-transcatheter arterial chemoembolization (TACE) glue damage or atrophy. Finally, EST was done in those cases.

Among the methods for relieving jaundice, the insertion of biliary stents, both metal and plastic, were most common (n=33, 61.1%). There were no severe procedure-related complications, such as perforation or death. Stent dysfunction developed in 8 patients during the follow-up period. Stent obstruction was observed in 4 patients caused by tu-
mor growth and thrombi. These 4 patients were treated by stent changes in 2 cases, stent-in-stent insertion in 1 case, and stent dilatation by ballooning in 1 case. Stent migration occurred in 1 patient. The causes of stent dysfunction in the other 3 patients were biloma leakage, bleeding at previous endoscopic sphincterotomy site, and infection due to huge abscess.

HCC is a hypervascular tumor; therefore, stent obstruction can easily be caused by intraluminal tumor thrombus or infiltration (type 1 obstructive jaundice). Three of 4 patients with stent obstruction showed type 1 obstructive jaundice due to intraluminal thrombus or tumor infiltration. The other one patient had type 3 jaundice (i.e., extraluminal lymph node compression). One patient with stent migration also showed type 1 jaundice.

There were no significant differences in age, sex, causes of hepatitis, the presence of cirrhosis, and treatment modalities of HCC between clinical success and failure groups. HCC patients that achieved clinical success were treated with TACE, chemotherapy, radiotherapy, or radiofrequency ablation.

The two groups did not differ in the mechanisms of obstructive jaundice, locations of biliary obstruction, and modalities of endoscopic interventions. However, mean total bilirubin was significantly higher (23.1±10.4 mg/dL vs. 8.1±5.3 mg/dL, \( p \leq 0.001 \)) and albumin was significantly lower (2.8±0.4 g/dL vs. 3.1±0.4 g/dL, \( p=0.013 \)) in clinical failure group than in the clinical success group. Furthermore, the cut-off value of pre-treatment total bilirubin level for predicting the clinical prognosis after endoscopic intervention was 12.8

### Table 2. Classification of Obstructive Jaundice in HCC

| Mechanisms of obstructive jaundice* | Number of patients (%) |
|-------------------------------------|------------------------|
| Intraluminal tumor thrombosis/infiltration | 17/35 |
| Hemobilia                           | 6                      |
| Extraluminal compression by tumor/node | 7/3                   |

Locations of obstruction

| Type I (IHD involvement without contralateral IHD involvement) | 8 (14.8) |
| Type II (IHD involvement with hilar involvement)            | 12 (22.2) |
| Type III (bilateral IHD involvement with hilar involvement) | 3 (5.6) |
| Type IV (solitary EHD involvement)                          | 6 (11.1) |
| Type V (multifocal involvement in both IHD and EHD)         | 8 (14.8) |
| Type VI (solitary hilar or CHD involvement)                 | 17 (31.5) |

*Each type of obstructive jaundice could have been counted more than once.

### Table 3. Endoscopic Interventions of Obstructive Jaundice in HCC

| Endoscopic interventions | Number of patients (%) |
|--------------------------|------------------------|
| ENBD                     | 6 (11.1)               |
| Plastic stent            | 17 (31.5)              |
| Metal stent              | 16 (29.6)              |
| EST                      | 12 (22.2)              |
| None                     | 3 (5.6)                |

Stent length, median 10 cm (range: 5–15 cm)

| ENBD, endoscopic nasobiliary drainage; EST, endoscopic sphincterotomy; HCC, hepatocellular carcinoma. |

### Table 4. Variables Predictive or Non-Predictive of Clinical Success and Failure for Endoscopic Intervention

|                                      | Clinical success (n=23) | Clinical failure (n=28) | \( p \) value |
|--------------------------------------|-------------------------|-------------------------|--------------|
| Total bilirubin (mg/dL)              | 8.1±5.3                 | 23.1±10.4               | <0.001       |
| Median days to normalization of total bilirubin or death (days) | 47                      | 45                      | 0.744        |
| Liver cirrhosis                     | 19                      | 26                      | 0.390        |
| Child-Pugh classification (A or B/C) | 17/6                    | 8/20                    | 0.001        |
| Albumin (g/dL)                      | 3.1±0.4                 | 2.8±0.4                 | 0.013        |
| Patients with alcoholic history     | 9                       | 20                      | 0.010        |
| Mechanisms of obstructive jaundice (type 1/2/3)* | 14/2/7                | 22/4/2                  | 0.092        |
| Locations of obstruction (type I/II/III/IV/V/VI) | 3/4/1/3/3/9         | 2/8/2/3/5/8             | 0.855        |
| Endoscopic interventions (ENBD/PS/MS/EST) | 3/11/8/1             | 3/6/8/8                 | 0.077        |
| Cancer treatment modality (Op./TACE/CTx/RTx/RFA/none) | 0/18/12/10/6/1       | 0/18/14/9/3/3           | 0.617        |

*Type 1, intraluminal obstruction; type 2, hemobilia; type 3, extraluminal compression.

†Type I, IHD involvement without contralateral IHD involvement; type II, IHD involvement with hilar involvement; type III, bilateral IHD involvement with hilar involvement; type IV, solitary EHD involvement; type V, multifocal involvement in both IHD and EHD; type VI, solitary hilar or CHD involvement.
Endoscopic Treatment of Obstructive Jaundice in HCC

Among various causes of jaundice, obstructive jaundice caused by HCC is rare. Obstructive jaundice in HCC was first reported in 1947 by Mallory, et al. In that case, the obstructive jaundice was due to invasion by HCC of the cystic duct, followed by hemobilia from tumor thrombi.

As obstructive jaundice can be relieved by active intervention, unlike hepatocellular jaundice, it is clinically important to be aware that bile duct obstruction can be a cause of jaundice in HCC, and distinguishing obstructive jaundice from non-obstructive jaundice should be performed.

The goals of management in patients with HCC associated obstructive jaundice are biliary decompression, and, if possible, removal of tumor debris. This can be done surgically or endoscopically. The choice of method is based on the nature and location of the main tumor mass, severity of the symptoms, associated neoplastic strictures, and the patient's overall status. Operative treatment is beneficial only in patients with extrahepatic intraluminal biliary obstruction. Therefore, in patients with advanced diseases, endoscopic interventions might be safer and more satisfactory, as a form of palliative treatment.

Obstructive jaundice can be further specified according to the mechanisms and locations of obstruction. First, mechanisms of biliary obstruction in HCC were divided into three types by Lai and Lau. These types included tumor invasion of a branch of the biliary tree; distal migration to the common bile duct by necrotic free floating fragments that separate from a biliary tumor thrombus; and hemobilia caused by bleeding from a tumor that causes the bile duct to fill with blood clots that can obstruct bile duct system. It is possible that the mechanisms of obstructive jaundice might affect the outcomes of endoscopic intervention. However, in our study, the mechanisms of biliary obstruction did not affect the results of intervention: we have to point out that
there were multiple mechanisms for obstructive jaundice in HCC, and sometimes it is hard to say which mechanism was dominant.

One must also consider which endoscopic interventional method should be used. According to our results, stenting did not always seem to be the best interventional method in HCC. Some HCC patients with obstructive jaundice treated with stent insertion showed inadequate relief of jaundice according to their underlying hepatic function. Therefore, stenting may not be of help for some patients with poor liver function. In such cases, stent insertion is not the best treatment for relieving jaundice. Brown and Covey\textsuperscript{13} suggested that stent placement is less effective in jaundice caused by intraductal tumor, because tumors can infiltrate into the stent, resulting in occlusion. Accordingly, we recommend choosing interventional methods on a case-by-case basis, taking into consideration the patient’s clinical condition.

By considering predictive factors, patients who are more likely to benefit from endoscopic intervention may be selected. We found that the factors influencing successful endoscopic management include hepatic function at the time of the endoscopic procedure and a history of alcohol consumption. Furthermore, median survival after endoscopic intervention in the clinical success group was notably longer than that in the clinical failure group. This implies that the factors that predict the success of endoscopic management, defined here as a relief of obstruction, also can predict median survival after the procedure. Many physicians are reluctant to treat patients with HCC that have jaundice. However, in well selected cases, endoscopic intervention not only can resolve obstructive jaundice, but also prolong the survival of patients.

We concluded that endoscopic intervention can be an effective way to relieve obstructive jaundice in patients with HCC and can lead to the improvement of quality of life and even survival therein. Liver function and a history of alcohol consumption should be checked to select patients most likely to benefit endoscopic interventions. Further prospective studies with larger population will be needed to objectively compare different methods of intervention. In the future, development of guidelines for endoscopic treatment in HCC patients with obstructive jaundice will be needed.

**REFERENCES**

1. Lai EC, Lau WY. Hepatocellular carcinoma presenting with obstructive jaundice. ANZ J Surg 2006;76:631-6.
2. Qin LX, Tang ZY. Hepatocellular carcinoma with obstructive jaundice: diagnosis, treatment and prognosis. World J Gastroenterol 2003;9:385-91.
3. Batsis JA, Halfdanarson TR, Pitot H. Extra-hepatic hepatocellular carcinoma presenting as obstructive jaundice. Dig Liver Dis 2006;38:768-71.
4. Ikenaga N, Chijiiwa K, Otani K, Ohuchida J, Uchiyama S, Kondo K. Clinicopathologic characteristics of hepatocellular carcinoma with bile duct invasion. J Gastrointest Surg 2009;13:492-7.
5. Peng SY, Wang JW, Liu YB, Cai XJ, Deng GL, Xu B, et al. Surgical intervention for obstructive jaundice due to biliary tumor thrombus in hepatocellular carcinoma. World J Surg 2004;28:43-6.
6. Mallory TB, Castleman B, Parris EE. Case records of the Massachusetts General Hospital. N Engl J Med 1947;237:673-6.
7. Chen MF. Icteric type hepatocellular carcinoma: clinical features, diagnosis and treatment. Chang Gung Med J 2002;25:496-501.
8. Buckmaster MJ, Schwartz RW, Carnahan GE, Strodel WE. Hepatocellular carcinoma embolus to the common hepatic duct with no detectable primary hepatic tumor. Am Surg 1994;60:699-702.
9. Hu J, Pi Z, Yu MY, Li Y, Xiong S. Obstructive jaundice caused by tumor emboli from hepatocellular carcinoma. Am Surg 1999;65:406-10.
10. Tantawi B, Cherqui D, Tran van Nhieu J, Kracht M, Fagniez PL. Surgery for biliary obstruction by tumour thrombus in primary liver cancer. Br J Surg 1996;83:1522-5.
11. Shiomi M, Kamiya J, Nagino M, Uesaka K, Sano T, Hayakawa N, et al. Hepatocellular carcinoma with biliary tumor thrombus: aggressive operative approach after appropriate preoperative management. Surgery 2001;129:692-8.
12. Jan YY, Chen MF. Obstructive jaundice secondary to hepatocellular carcinoma rupture into the common bile duct: choledochoscopic findings. Hepatogastroenterology 1999;46:157-61.
13. Brown KT, Covey AM. Management of malignant biliary obstruction. Tech Vasc Interv Radiol 2008;11:43-50.